BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013;28:193-9. [DOI: 10.1007/s11011-013-9376-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hey P, Gow P, Testro AG, Apostolov R, Chapman B, Sinclair M. Nutraceuticals for the treatment of sarcopenia in chronic liver disease. Clin Nutr ESPEN 2021;41:13-22. [PMID: 33487256 DOI: 10.1016/j.clnesp.2020.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
2 Martí-carvajal AJ, Gluud C, Arevalo-rodriguez I; Cochrane Hepato-Biliary Group. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011451] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Malaguarnera G, Catania VE, Francaviglia A, Malaguarnera M, Drago F, Motta M, Latteri S. Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis. Aging Clin Exp Res 2017;29:185-90. [PMID: 27822883 DOI: 10.1007/s40520-016-0653-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
4 Yang Y, Choi H, Lee CN, Kim YB, Kwak YT. A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Efficacy of Acetyl-L-carnitine in Patients with Dementia Associated with Cerebrovascular Disease. Dement Neurocogn Disord 2018;17:1-10. [PMID: 30906386 DOI: 10.12779/dnd.2018.17.1.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Malaguarnera G, Latteri S, Catania VE, Malaguarnera M. Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels. J Thorac Dis 2017;9:2332-6. [PMID: 28932535 DOI: 10.21037/jtd.2017.08.67] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abbasnezhad A, Choghakhori R, Kashkooli S, Alipour M, Asbaghi O, Mohammadi R. Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy: A systematic review and meta-analysis. J Gastroenterol Hepatol 2019;34:2062-70. [PMID: 31254469 DOI: 10.1111/jgh.14765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
7 Said VJ, Garcia-trujillo E. Beyond Lactulose: Treatment Options for Hepatic Encephalopathy. Gastroenterology Nursing 2019;42:277-85. [DOI: 10.1097/sga.0000000000000376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bo L, Liu Y, Jia S, Liu Y, Zhang M, Li S, Zhao X, Sun C. Metabonomics analysis of quercetin against the nephrotoxicity of acrylamide in rats. Food Funct 2018;9:5965-74. [DOI: 10.1039/c8fo00902c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
9 Salim T, Stark SA, Duarte-rojo A. Food as Therapy for Frailty. Curr Hepatology Rep 2020;19:23-9. [DOI: 10.1007/s11901-020-00509-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
11 Wang T, Suzuki K, Kakisaka K, Onodera M, Sawara K, Takikawa Y. L‐carnitine prevents ammonia‐induced cytotoxicity and disturbances in intracellular amino acid levels in human astrocytes. Journal of Gastroenterology and Hepatology 2019;34:1249-55. [DOI: 10.1111/jgh.14497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
12 Iwasa M, Takei Y. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia: Management of hepatic encephalopathy. Hepatol Res 2015;45:1155-62. [DOI: 10.1111/hepr.12495] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
13 Sergi G, Pizzato S, Piovesan F, Trevisan C, Veronese N, Manzato E. Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders. Aging Clin Exp Res 2018;30:133-8. [PMID: 28534301 DOI: 10.1007/s40520-017-0770-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
14 Meng L, Shi H, Wang D, Shi J, Wu W, Dang Y, Fan G, Shen J, Yu P, Dong J, Yang R, Xi H. Specific Metabolites Involved in Antioxidation and Mitochondrial Function Are Correlated With Frailty in Elderly Men. Front Med 2022;9:816045. [DOI: 10.3389/fmed.2022.816045] [Reference Citation Analysis]
15 Wang T, Suzuki K, Chiba T, Kakisaka K, Takikawa Y. Supplementation with Branched-Chain Amino Acids Induces Unexpected Deleterious Effects on Astrocyte Survival and Intracellular Metabolism with or without Hyperammonemia: A Preliminary In Vitro Study. Int J Hepatol 2021;2021:7615126. [PMID: 34712496 DOI: 10.1155/2021/7615126] [Reference Citation Analysis]
16 Rajpurohit S, Musunuri B, Shailesh, Mohan PB, Shetty S. Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.01.012] [Reference Citation Analysis]
17 Chen N, Yang M, Zhou M, Xiao J, Guo J, He L. L-carnitine for cognitive enhancement in people without cognitive impairment. Cochrane Database Syst Rev 2017;3:CD009374. [PMID: 28349514 DOI: 10.1002/14651858.CD009374.pub3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
18 Pennisi M, Lanza G, Cantone M, D'Amico E, Fisicaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, Malaguarnera G. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020;12:E1389. [PMID: 32408706 DOI: 10.3390/nu12051389] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
19 Pennisi M, Bertino G, Gagliano C, Malaguarnera M, Bella R, Borzì AM, Madeddu R, Drago F, Malaguarnera G. Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. Nutrients 2017;9:E897. [PMID: 28820468 DOI: 10.3390/nu9080897] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
20 Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Mala-guarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon. 2014;14:e11608. [PMID: 24910702 DOI: 10.5812/hepatmon.11608] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
21 Pennisi M, Malaguarnera G, Puglisi V, Vinciguerra L, Vacante M, Malaguarnera M. Neurotoxicity of acrylamide in exposed workers. Int J Environ Res Public Health 2013;10:3843-54. [PMID: 23985770 DOI: 10.3390/ijerph10093843] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
22 Bin-Jumah M, Abdel-Fattah AM, Saied EM, El-Seedi HR, Abdel-Daim MM. Acrylamide-induced peripheral neuropathy: manifestations, mechanisms, and potential treatment modalities. Environ Sci Pollut Res Int 2021;28:13031-46. [PMID: 33484463 DOI: 10.1007/s11356-020-12287-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
23 Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev 2015;90:55-68. [PMID: 25895618 DOI: 10.1016/j.addr.2015.04.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
24 Jiang Q, Jiang G, Shi K, Cai H, Wang Y, Zheng M. Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Annals of Hepatology 2013;12:803-9. [DOI: 10.1016/s1665-2681(19)31323-7] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
25 Suzuki K, Endo R, Takikawa Y, Moriyasu F, Aoyagi Y, Moriwaki H, Terai S, Sakaida I, Sakai Y, Nishiguchi S, Ishikawa T, Takagi H, Naganuma A, Genda T, Ichida T, Takaguchi K, Miyazawa K, Okita K. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res. 2018;48:411-423. [PMID: 29235218 DOI: 10.1111/hepr.13045] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
26 Childs E. Influence of energy drink ingredients on mood and cognitive performance. Nutr Rev 2014;72 Suppl 1:48-59. [PMID: 25293543 DOI: 10.1111/nure.12148] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
27 Pennisi M, Lanza G, Cantone M, D'Amico E, Fisicaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, Malaguarnera G. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020;12:E1389. [PMID: 32408706 DOI: 10.3390/nu12051389] [Reference Citation Analysis]
28 Malaguarnera G, Catania VE, Bonfiglio C, Bertino G, Vicari E, Malaguarnera M. Carnitine Serum Levels in Frail Older Subjects. Nutrients 2020;12:E3887. [PMID: 33352627 DOI: 10.3390/nu12123887] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Mangini C, Montagnese S. New Therapies of Liver Diseases: Hepatic Encephalopathy. J Clin Med 2021;10:4050. [PMID: 34575157 DOI: 10.3390/jcm10184050] [Reference Citation Analysis]
30 Malaguarnera G, Pennisi M, Bertino G, Motta M, Borzì AM, Vicari E, Bella R, Drago F, Malaguarnera M. Resveratrol in Patients with Minimal Hepatic Encephalopathy. Nutrients 2018;10:E329. [PMID: 29522439 DOI: 10.3390/nu10030329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
31 Rivera-Espinosa L, Floriano-Sánchez E, Pedraza-Chaverrí J, Coballase-Urrutia E, Sampieri AI, Ortega-Cuellar D, Cárdenas-Rodríguez N, Carmona-Aparicio L. Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy. Int J Mol Sci 2013;14:16184-206. [PMID: 23921686 DOI: 10.3390/ijms140816184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Xu H, Geng S, Li T, Fu Q, Lu S, Liang X, Lu Y, Zhang M, Yang X, Lu K. Maturation of buffalo oocytes in vitro with acetyl-L-carnitine improves cryotolerance due to changes in mitochondrial function and the membrane lipid profile. Reprod Fertil Dev 2019;31:386. [DOI: 10.1071/rd18102] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2019;1:CD011451. [PMID: 30610762 DOI: 10.1002/14651858.CD011451.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Jamilian H, Jamilian M, Samimi M, Afshar Ebrahimi F, Rahimi M, Bahmani F, Aghababayan S, Kouhi M, Shahabbaspour S, Asemi Z. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol 2017;33:442-7. [PMID: 28277138 DOI: 10.1080/09513590.2017.1290071] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
35 Sato S, Namisaki T, Furukawa M, Saikawa S, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Kitagawa K, Moriya K, Akahane T, Mitoro A, Hoki N, Ann T, Yoshiji H. Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis. Biomed Rep 2020;13:65. [PMID: 33149909 DOI: 10.3892/br.2020.1372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]